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Objectives: Time to 12-week confirmed disability progression, measured by the 
Expanded Disability Status Scale (EDSS), is a key endpoint in RRMS trials. However, 
the EDSS has widely discussed limitations, and several therapies have shown 
inconsistent results for this endpoint in terms of statistical significance. Here 
we contextualize differences in 12-week confirmed disability progression results 
in the Phase 3 studies of gastro-resistant dimethyl fumarate (DMF), DEFINE and 
CONFIRM. MethOds: Time to 12-week confirmed disability progression at 2 years 
was a secondary endpoint in both studies; however, the studies were not powered 
to detect statistical significance for this endpoint. Patients had the option of dis-
continuing study treatment and initiating alternative therapy at any time due to 
12-week confirmed disability progression or after completing 48 weeks of study 
treatment and experiencing one confirmed relapse after 24 weeks (DEFINE) or two 
confirmed relapses at any time (CONFIRM). Results: Although gastro-resistant 
DMF 240mg BID demonstrated consistent reductions on 12-week confirmed dis-
ability progression, statistical significance was achieved in DEFINE (p= 0.0050) but 
not CONFIRM (p= 0.2536). There was an apparent difference in the placebo rate 
of 12-week confirmed disability progression at 2 years (DEFINE, 27%; CONFIRM, 
17%). In CONFIRM, a relatively higher percentage of placebo patients (4.1%) versus 
gastro-resistant DMF patients (1.7%) switched to alternative MS therapy or with-
drew after the time of tentative disability progression without a subsequent EDSS 
assessment. Additionally, a relatively higher percentage of placebo patients who 
switched to alternative MS therapy had ≥ 2 relapses without 12-week confirmed 
disability progression prior to switch in CONFIRM (45%) compared with DEFINE 
(16%). cOnclusiOns: Relapse-based criteria for switching to alternative therapy 
may have contributed to the lower placebo progression rate and decreased assay 
sensitivity for this particular endpoint in CONFIRM. The totality of evidence needs 
to be taken into account when assessing a therapy’s effect on disability progression.
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Objectives: To examine annual prevalence and treatment rates of multiple 
sclerosis (MS) patients using a large US commercial administrative claims data-
base. MethOds: Random sample of 5 million lives from the IMS LifeLink Plus 
database was used for this analysis. Individuals with ≥ 1 month eligibility were 
included in the denominator; those with ≥ 1 month eligibility and an MS diagnosis 
(ICD-9-CM: 340. xx) were included in the numerator. Presence of a disease-modifying 
drug (DMD) was defined as ≥ 1 claim during the calendar year of interest. Baseline 
demographics and clinical characteristics were evaluated for each group. Annual 
prevalence (per 10,000) and treatment rates were reported for each calendar year 
(2006–2012) and were further stratified by age and gender. Results: MS patients 
were older than patients without MS (mean age range 46.8–47.7 vs. 34.4-35.1, respec-
tively) and more likely to be female (73% vs. 51%, respectively). Comorbidities such as 
gastrointestinal disorders (42.8%), hypertension (43.5%), arthritis (24.8%) and anxiety 
(22.8%) were common among MS patients (2006 estimates). MS prevalence ranged 
from 16.4/10,000 (2006) to 17.8/10,000 (2010). Similar patterns over the years were 
observed when data were stratified by sex and age, with absolute rates being higher 
among women vs. men (24.4/10,000 vs. 8.2/10,000, respectively; 2012; P< 0.001) and 
patients aged 45–64 years (29.4/10,000 vs. 0.4/, 15.6/ and 18.2/10,000 patients aged 
< 18, 18–44 and ≥ 65, respectively; P< 0.001). The proportion of MS patients receiv-
ing a DMD increased from 2006 (42.5%) to 2012 (51.2%) (P< 0.001). Similar rates and 
trends in the proportion of patients with a DMD were observed when stratified 
by gender (42.8% (2006) and 51.3% (2012) [female]; 41.5% (2006) and 50.7% (2012) 
[male]; both P< 0.001). cOnclusiOns: In a recent 5-year period, MS prevalence 
in a large US insured population increased slightly, with a greater increase in the 
likelihood of DMD use.
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Objectives: Multiple Sclerosis (MS) is a chronic disease of the Central Nerve 
System. The aim of this paper is to characterize the various clinical and demographi-
cal feature of the MS population. MethOds: In a 6-month cross-sectional study248 
patients were investigated in Khorasan provinces. Data was collected by employing 
a 32- item self-administered questionnaire in a face to face interview. Results: 
A total of 248 patients were recruited (186 female, 75%; 62 male, 25%). The mean 
age was 31.9±8.7, the mean onset age was 26.3 (26.3±8: 1) and the median dura-
tion of illness was 3.8 years. The prevalence and incidence were estimated to be 
25/100000 and 2.5/100,000 respectively. Significantly more patients had a Relapsing 
Remitting MS course. Self reported character of MS individuals were significantly 
more (193, 77.8%) regarding nervous character (p value= .000). A family history of 
ms was reported in 11%. However, there was no a significant difference between 
men and women with respect to age, age of onset, BMI, disease duration and gap 
between clinical onset and diagnosis. The education level was reported as 154 (62%) 
had a bachelor and greater degree and 94 (38%) had a diploma or under-diploma 
degree. Thirty six percents of the patients were born in the spring. cOnclusiOns: 
In contrast to reports from Caucasians, the Iranian differs with respect to age, age 
of onset of illness, disease duration, family history, sex ratio. The sex ratio of 3: 1 
in this study is somewhat higher than the usual 2: 1 in the standard text and seen 
in Asia or the neighboring Arab countries. This might reflect the role of hormone 
or genetic factors or much more visiting by women, or women stressful life. These 
included BMI, birth season, education stand. The educated people in developing 
country are probably likely to adopt a “western” lifestyle, therefore more probably 
to get the risk of developing Western disease.
ment of the catheter tip was associated with fewer shunt failures, as demonstrated in 
9 clinical studies investigating accurate catheter placement using the AxiEM™ IGNS 
(Medtronic Inc). In addition to being costly, studies showed shunt revision surgery 
was associated with significant morbidity and lower long-term QOL. In a study of 80 
paediatric Hydrocephalus patients, investigators found that patients with a history 
of two or more shunt revision surgeries had a significantly worse QOL (p< 0.02), as 
measured by the Hydrocephalus Outcomes Questionnaire (HOQ). cOnclusiOns: The 
use of IGNS significantly increases the accuracy of ventricular catheter placement 
compared to freehand techniques in hydrocephalus patients undergoing ventricular 
shunt insertion. Clinical studies have shown the use of IGNS in shunt placement 
surgery results in lower shunt failure rates, which improve QOL and lowers the eco-
nomic impact to payers.
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Objectives: Teriflunomide and dimethyl fumarate (DMF), oral therapies for relaps-
ing–remitting multiple sclerosis (RRMS), have demonstrated efficacy in clinical trials. 
Despite challenges in comparing outcomes across studies, exploratory analyses 
of treatment effects can be compared informally using relative reductions in a 
specific endpoint. However, these outcomes do not account for differences in dis-
ease severity among study populations or differences on very low event rates. The 
number needed to treat (NNT) to prevent an event is an important outcome to 
consider for any comparisons within the field of MS. MethOds: NNTs were derived 
using data from studies with teriflunomide 14 mg (TEMSO, NCT00134563; TOWER, 
NCT00751881) or DMF (DEFINE, NCT00420212; CONFIRM, NCT00451451) based on 
inverse of absolute differences between treatment and placebo groups. Results: 
Teriflunomide studies included patients with progressive disease; patients in 
DEFINE had slightly lower Expanded Disability Status Scale scores. Teriflunomide 
and DMF significantly reduced risk of relapse (all studies). NNTs to prevent one 
relapse were similar across studies (5.9 [TEMSO], 5.6 [TOWER], 5.3 [DEFINE], 5.6 
[CONFIRM]). Risk of disability progression sustained for 12 weeks was significantly 
reduced in TEMSO, TOWER, and DEFINE but not CONFIRM. Corresponding NNTs to 
prevent disability progression were 13.8, 17.4, 10.8, and 30.2. Risk of relapse leading 
to hospitalization was significantly reduced in TEMSO and TOWER but not in DEFINE 
and CONFIRM. Corresponding NNTs were lower in TEMSO (12.5) and TOWER (20) 
than in DEFINE (50) and CONFIRM (50). cOnclusiOns: Using the NNT approach, we 
demonstrate a comparable effect size for teriflunomide and DMF on relapse. NNTs 
to prevent disability progression with teriflunomide showed a consistent signifi-
cant reduction in risk versus placebo in both TEMSO and TOWER, whereas for DMF, 
comparable NNTs were observed only in DEFINE, and not in CONFIRM. Reduction 
of risk for relapse leading to hospitalization was significant only for teriflunomide.
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Objectives: Alzheimer’s Disease (AD) destroys brain cells, causing problems 
with memory, thinking, and behavior severe enough to affect work, family and 
social relationships, and basic activities of daily living. AD gets worse over time, 
it is incurable and fatal. Donepezil, galantamine, rivastigmine and memantine 
are the current treatment options but the latest evidence was not systematically 
reviewed recently. MethOds: PubMed, Health Technology Assessment Database, 
NHS Economic Evaluation Database, Cochrane Central Register of Controlled 
Trials, Cochrane Database of Systematic Reviews, DAHTA-Datenbank, PSYNDEX 
and PsycINFOwere searched systematically for randomized-controlled studies. 
For the abstracts that met the pre-defined inclusion criteria, full text articles were 
obtained. The abstracts that did not meet the search criteria were excluded. Based 
on these manuscripts it was evaluated whether each study meets the selection cri-
teria. Results: After elimination of duplicates the search indicated above yielded 
418 articles of which another 299 were excluded based on the title selection; after 
abstract review, 82 articles have been reviewed in full text which were also deemed 
to be relevant based on the research question. For donepezil 24 RCTs were available 
for which another 4 subgroup and exploratory analyses have been published. For 
galantamine 11 RCTs with 6 exploratory analysis are available. For rivastigmine 10 
RCTs are available with 7 exploratory papers. For memantine 14 RCTs with 6 explora-
tory analysis were found. Out of those studies eleven head-to-head studies are avail-
able; 5 studies comparing donepezil vs memantine, 3 studies comparing donepezil vs 
rivastigmine and one study each comparing donepezil vs galatamine, rivastagmine 
vs memantine. There was one study comparing rivastagmine vs donepezil vs galan-
tamine. In comparison the clinical evidence seems diverse dependent on the patient 
characteristics, study duration, and severity of disease. cOnclusiOns: Appropriate 
evidence assessment for the approved AD treatments requires clinical expertise and 
close review of the study characteristics.
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of shunt infections uses a disproportionate amount of hospital expenditure (71% of 
total management costs or € 57,650 per patient) when compared to shunt revision 
surgery (29% of total costs or € 6,720 per patient). Using shunt implant data from 
the UK Hospital Episode Statistics (HES), procedures and interventions database, 
we estimated the potential cost savings to the UK Health Care system in 2012-13 
was £1,461,207 if all new lumboperitoneal or ventriculoperitoneal shunt surgeries 
were performed using AISC systems. cOnclusiOns: Current clinical evidence has 
demonstrated AISC reduce infection rates in shunted Hydrocephalus patients. The 
potential health care savings associated with reduced infection rates are significant.
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Objectives: In recent years, fingolimod and natalizumab - though expensive - have 
brought significant improvements in second-line treatment of Multiple Sclerosis 
(MS). In Italy, fingolimod was acknowledged in 2011 the therapeutic innovation 
criterion which exempts the manufacturer from a mandatory discount of 5% on 
the ex-factory price for a three-year period. Since the innovation period is soon 
expiring and in order to assess the affordability of this therapy for the National and 
Regional Healthcare Systems (HSs), we performed a Budget Impact Analysis (BIA) 
of fingolimod in second-line treatment of MS, enclosed an ethical assessment of 
justice issues. MethOds: A model in MSExcel was built to perform the BIA on five 
Regions located in the Nord, Centre and South of Italy. Interviews with regional 
stakeholders/clinicians provided information about epidemiology, market share, 
patient journey and resource consumption in the respective regions. Costs were 
calculated using regional tariffs for outpatient/inpatient health care services. The 
time horizon is three years which is the timeframe mostly requested by Healthcare 
Authorities. Results: Preliminary results conducted for Lazio and Sicily show that, 
in second line, the use of fingolimod compared to natalizumab leads to savings of 
€ 2,500 per patient in Lazio and € 2,700 in Sicily due to lower consumption of health 
care resources (different drug administration and patient management). The BIA 
shows that fingolimod can determine savings up to € 3.4 million approximately 
in Lazio and € 2.2 million in Sicily. Furthermore, if patients with frequent relapses 
in first line were early switched to second line, savings could be even higher: an 
additional € 2.0 million for Lazio and € 0.6 million for Sicily in the first year of treat-
ment. cOnclusiOns: The present analysis shows that, despite innovation expiry, 
spending remains sustainable for fingolimod in the Italian and Regional HSs. 
Analyses on the other Regions must be performed to confirm such results.
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Objectives: Relapsing-remitting multiple sclerosis (RRMS), the most common 
form of MS, imposes a considerable cost burden on health care systems. Glatiramer 
acetate 20mg/mL, a once-daily injectable disease modifying therapy (DMT), has 
long-term real-world efficacy (more than two million patient/years exposure) for 
the treatment of RRMS. An economic model was developed to estimate the financial 
impact on the UK health care system of switching RRMS treatments from glati-
ramer acetate to emerging oral (teriflunomide and dimethyl fumarate) and infused 
(alemtuzumab) DMTs over five years. MethOds: The eligible patient population 
in the model was estimated based on RRMS incidence rates, and the proportion 
of people receiving glatiramer acetate in the UK in 2013 (based on market share 
data). Medication costs were derived from British National Formulary list prices, 
while treatment administration, initiation and monitoring costs were calculated 
from UK health care unit and hospital tariff codes taking account of requirements 
specified in Summary of Product Characteristics documentation. Results: The 
model estimated that 5,900 people with RRMS were receiving glatiramer acetate in 
the UK in 2013, corresponding to 17.8% of those currently receiving DMTs. Assuming 
progressive switching within the eligible RRMS population from glatiramer acetate 
to teriflunomide (from 1–6% in year one to five), dimethyl fumarate (1–6%) and 
alemtuzumab (1–3%), additional spending of £17.0 million, £65.3 million and £147.6 
million over one, three and five years, respectively, was incurred. This was primarily 
driven by higher acquisition costs compared with glatiramer acetate. Administration 
requirements associated with alemtuzumab, and the initiation and monitoring 
requirements of the oral DMTs also contributed to additional costs. cOnclusiOns: 
No data exist supporting the clinical superiority – and therefore associated eco-
nomic benefit – of the emerging DMTs over glatiramer acetate; switching patients 
from glatiramer acetate to new therapies may be associated with substantial costs 
for the UK health care system.
PND20
imPRoviNg cliNicAl outcomes AND heAlth cARe ResouRces 
utilizAtioN iN multiPle scleRosis: A PoRtuguese hosPitAl PeRsPective
Viriato D., Carrasco J., Fonseca J, Pacheco R.
Novartis, porto Salvo, portugal
Objectives: In Portugal there are about 2,694 patients treated with interferon 
beta (IFNB) and it is estimated that 30.4% are poor responders. Fingolimod treat-
ment costs are an obstacle to treatment escalation, despite the fact that early 
initiation of fingolimod may impact favorably on long-term clinical outcomes. 
PND15
ePiDemiology of multiPle scleRosis iN lAtiN AmeRicA: cRiticAl 
ANAlysis of the liteRAtuRe
Einarson T.R.1, Bereza B.1, Machado M.2
1University of Toronto, Toronto, ON, Canada, 2Biogen Idec, São paulo, Brazil
Objectives: To summarize rates of prevalence, incidence and types of multiple 
sclerosis (MS) in Latin America. MethOds: We searched Medline, Embase, Scielo 
and LILACS using key words “multiple sclerosis” and “esclerosis múltiple”, plus 
“Latin America” and all country names. Accepted were full articles or abstracts 
reporting original research in any language at any time, with MS diagnosed using 
any acceptable criteria. Clinically isolated syndrome was excluded. Results: 1482 
articles were identified and 203 reviewed in full; 88 were rejected and 115 were 
analyzed (38 prevalence, 3 incidence, 2 both, 72 clinical epidemiology), including 
68 (59%) full text and 47 (41%) abstracts. Studies originated in 14 countries, mostly 
larger, more affluent nations (47% Brazil, 15% Argentina, 8% Mexico). Prevalence 
studies examined 19,357 MS cases from 1968-2012; rates ranged from 0 in a group 
of Mexican natives to 52/100,000 in Puerto Rico, with a mean of 13.9/100,000. This 
range would be classified as low to medium, with 83,000 (CI95%: 62,000-104,000) 
prevalent cases in Latin America. Incidences ranged from 0.15/100,000 person-
years in Panama to 1.76 in Argentina (median= 1.32, mean= 1.35), or 7,887-8,365 new 
cases/year in Latin America. Authors noted increasing prevalence and incidence 
rates over time. Clinical epidemiology MS data were obtained from 94 studies; 66% 
used Poser criteria, 48% McDonald (various versions), and 14% other, from 19,893 
patients (72% females). The average age at assessment was 38.2 and 32.2 at disease 
onset with average EDSS of 3.1. The relapsing-remitting form was most prevalent 
(74% of cases), followed by secondary progressive (12%) and primary progressive 
(10%). cOnclusiOns: MS prevalence and incidence rates vary widely in Latin 
America in a low to medium range, but are increasing as reported in the reviewed 
studies. Information is scant with many gaps. More research is needed to provide 
a basis for decision making and budget allocation.
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Objectives: The association between Parkinson’s disease (PD) and prostate can-
cer (PCA) is under discussion. We investigated whether exposure to entacapone 
increases risk of PCA by comparing PCA incidence and mortality rates in PD patients 
treated with levodopa and dopa decarboxylase inhibitors (DDCIs) with or without 
entacapone as an adjuvant. MethOds: This was a retrospective population-based 
register cohort study in Finland. Male PD patients exposed to levodopa/DDCI with 
entacapone and patients on levodopa/DDCI without entacapone between 1998 and 
2009 were identified from the Finnish Prescription Register. Concomitant treat-
ment with dopamine agonists (DA) and monoamine oxidase B (MAO-B) inhibitors 
was allowed. PCA cases and PCA deaths were identified from the Finnish Cancer 
Register and from the Cause of Death Register. PCA Incidence and mortality of 
PCA were modeled by Cox’s proportional hazards model with adjustments for rel-
evant baseline and time-dependent variables. The robustness of the findings for 
PCA incidence was evaluated in sensitivity analyses with alternative definitions 
for exposure and by using a nested case-control study setting with 4-5 individually 
matched controls randomly selected for each incident prostate cancer case within 
the cohort. Results: The study cohort consisted of 11 396 male patients. During a 
mean follow-up time of 4.7 years 359 PCA cases and 89 PCA deaths were observed. 
Entacapone use with levodopa/DDCI did not increase the risk of PCA incidence 
[hazard ratio (HR) 1.05, 95% CI 0.76-1.44] or PCA mortality (HR 0.93,95% CI 0.43-1.98) 
when compared to levodopa/DDCI without entacapone. For cumulative entacapone 
use (exposure > 360 days vs. never use) the HR was 0.82 (95% CI 0.56-1.18) for PCA 
incidence and 1.27 (95% CI 0.60-2.72) for PCA mortality. The results for PCA incidence 
were found robust in the sensitivity analyses. cOnclusiOns: No increased risk in 
PCA incidence or PCA mortality was seen in relation to entacapone use.
NeuRologicAl DisoRDeRs – cost studies
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bAckgROund: Shunt infections are one of the most serious and costly compli-
cations associated with shunt therapy. They can have long-term consequences 
to the patient and impose significant burden on the family and health care sys-
tem. Objectives: To investigate the clinical and economic value of AISC in the 
treatment of Hydrocephalus. MethOds: A search of the Embase, PubMed, and NHS 
EED electronic databases was conducted to identify studies evaluating the effective-
ness, efficacy and economic aspects of AISC’s in patients with Hydrocephalus. No 
language restrictions were applied. Results: Twenty-three clinical and 9 economic 
studies were included for review. The majority of published studies using AISC 
in the treatment of hydrocephalus demonstrated a statistically significant reduc-
tion in shunt-associated infections when AISC vs. standard shunt (SS) catheters 
were used. One meta-analysis of 14 studies that compared patients implanted with 
AISC to SS catheters showed AISC to be protective against shunt infection in both 
paediatric and adult Hydrocephalus patients. The pooled infection rate decreased 
from 7.0% in the SS catheter group to 3.5% in the AISC group. Economic studies 
conducted globally reported significant cost savings associated with using AISC. 
One study in paediatric Hydrocephalus patients found that ongoing management 
